Biotech M&A Hits $106 Billion, on Pace for Best Year Since 2019

Global biopharma dealmaking is running at a record clip, CNBC reported Thursday, with biotech M&A 2026 totals reaching $106 billion across 201 transactions in just the first half of the year. If that pace holds, annual deal value could surpass $250 billion and mark the sector’s strongest performance since the 2019 pre-pandemic peak.

Patent Cliffs Drive Urgency

The central pressure behind the activity is straightforward. Major drugmakers face steep revenue drops as top-selling medicines lose patent protection over the next several years. HSBC Head of Life Sciences and Healthcare Equity Research Rajesh Kumar told CNBC that companies are effectively replacing holes in their profit-and-loss statements before those cliffs arrive. Kumar described pharma giants as aggressively acquiring assets, suggesting the buying spree shows little sign of discipline-driven restraint.

That urgency follows a bumpy recent history. Deal activity bottomed out in 2022 after the pandemic distorted valuations across the sector. A softer 2024 saw total deal value settle near $114.8 billion before surging back to $209 billion in 2025. The momentum has only intensified heading into this year.

Bolt-On Deals Dominate the Landscape

Rather than pursuing headline-grabbing mega-mergers, most acquirers are focusing on targeted transactions in the $1 billion to $5 billion range. Nanna Lüneborg, general partner at life sciences venture capital firm Forbion, told CNBC these so-called bolt-on deals are easier to integrate and carry fewer antitrust complications than larger combinations. GSK’s recent $2.2 billion acquisition of RAPT Therapeutics is a prime illustration of that approach.

According to PitchBook data cited by CNBC, strategic and corporate add-on deals are absorbing the bulk of capital, with drug discovery assets drawing the most interest. The average deal size has climbed sharply to $527.3 million so far in 2026, up from $365 million across all of last year.

A Sector With Selective Momentum

Not every company enters this environment from the same position. Kumar noted that firms with strong organic growth, such as Eli Lilly, attract partnership interest naturally. Companies facing steeper patent cliffs and uncertain pipelines operate from a more pressured footing, making the strategic calculus harder.

Lüneborg pushed back on the idea that the buying wave reflects panic. She described the activity as deliberate across multiple therapeutic areas including oncology, metabolic disease, and central nervous system conditions such as Alzheimer’s. Acquirers are pursuing near-commercial assets while also seeding earlier-stage investments for longer-term technology access.

The rate environment has added friction. Kumar acknowledged that rising borrowing costs, driven partly by inflationary pressures linked to recent geopolitical disruptions, have made the second half of the year somewhat less accommodating for deal financing than the first. Still, the underlying need to replenish depleted pipelines continues to outweigh those headwinds.

Read Next: Novo Nordisk’s GLP-1 Lead Forces Investors to Rethink Eli Lilly’s Dominance